$27.100
-0.843 (-3.11%)收盘时
ELMD 资讯
ELMD 事件
Nasdaq Composite Rebounds, Micron Up 2.5%
Major indices rebounded from Monday's sell-off, led by tech-heavy Nasdaq Composite, as AI CapEx-themed trade showed some clear resurgence. Semiconductors, Computer Hardware, Communication Equipment, and Memory stocks traded notably firmer. Micronbounced 2.5%, Seagateand Western Digitalwere up over 3%, while Nvidia- heading into tomorrow's earnings - was up 2.2% on the day. Meanwhile, investors rotated out of Energy names - the worst performing sector in the S&P 500 today - as WTI Crude Oil pulled back by over $6 to $81 a barrel as the White House moves to exert greater economic pressure on Tehran to resolve the standoff over the Strait of Hormuz. In the opening hour of the evening session, index futures are flat heading into Wednesday's PCE inflation report as well as a tech earnings-rich afterhours session.In fixed income, although commentary regarding the efficacy of the "Bessent put" announced last Wednesday remains mixed, Treasuries are notably higher this week. On Tuesday, the yield on the 10-year note fell another 7 basis points to 4.64%. The perceived "dollar debasement" from the U.S. Treasury action is also keeping the greenback under pressure while supporting precious metals - gold briefly broke above $4,750 overnight, though silver remains capped below $70 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Semtechup 3.4%HEICO Corporationup 2.4%DOWN AFTER EARNINGS -Qfin Holdingsdown 12.8%Intuitdown 9.3%nCinodown 5.6%Zoom Communicationsdown 4.0%Electromeddown 2.0%Boxdown 0.6%ALSO LOWER -Spyre Therapeuticsdown 10.1% after results from RA sub-study of SKYWAY basket trial
Electromed President and CEO Jim Cunniff to Retire on April 2, 2027
Electromed announced that Jim Cunniff expects to retire as President and Chief Executive Officer, on or about April 2, 2027. Upon his retirement, he will resign from the Company's Board of Directors. The Board of Directors intends to conduct a national search for Electromed's next President and Chief Executive Officer and has engaged an executive search firm to assist in the process.
Electromed Reports Q4 Revenue of $19.4M
Reports Q4 revenue $19.4M, consensus $19.3M. "Fiscal 2026 was another exceptional year for Electromed, as the company generated record revenues and profits. The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth. Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage," said Jim Cunniff, Electromed's President and Chief Executive Officer. "Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to serve the approximately 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest(R) therapy. Our robust balance sheet with $20.5 million in cash, and recognition as one of Minnesota's fastest-growing public companies has Electromed well-positioned for durable, long-term growth and value creation for our investors."
Electromed Reports Q3 Revenue of $18.6M
Reports Q3 revenue $18.6M, consensus $17.6M. "I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected," said Jim Cunniff, President and Chief Executive Officer. "We continue to make investments in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth."
Electromed Reports Q2 Revenue of $18.9M
Reports Q2 revenue $18.9M, consensus $18.1M. "I'm thrilled to share our record results for the second quarter of fiscal 2026, which represented our 13th consecutive quarter of year-over-year revenue and net income growth. The Electromed team is executing our strategic growth plan at a high level, delivering over 16% revenue growth accompanied by strong operating leverage and net income of $0.32 per diluted share, a record for Electromed," said Jim Cunniff, Electromed's President and Chief Executive Officer. "Our Triple Down on Bronchiectasis marketing campaign is generating tremendous physician and patient awareness as we work to serve the nearly 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest(R) system. Our strong operational execution, investments in profitable growth, judicious stock buybacks, and maintenance of a strong balance sheet reflect our commitment to driving superior value to our shareholders. Most importantly, we remain dedicated to our mission of helping patients with compromised pulmonary function breathe easier and enjoy an improved quality of life."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。